U.S. sequential growth expected
Management expects steady sequential growth in U.S. revenue, with no decline anticipated.
GLAND / guidance tracker
Keep management guidance in view.
Gland Pharma · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
Cenexi margin improvement in 1-2 quarters
Cenexi EBITDA margins are expected to improve in the next 1-2 quarters through operational efficiencies.
Enoxaparin run rate to normalize from Q2
Enoxaparin sales are expected to pick up from next quarter as inventory rationalization ends.
40+ product launches planned for FY24
Total product launches in FY24 will be higher than normal due to relaunches, exceeding 40.
Base business mid-teens revenue growth for FY25
Management expects base business (ex-Cenexi) to grow in mid-teens for the full fiscal year.
Base business EBITDA margin 30-33% for FY25
Management guided base business EBITDA margin in the range of 30-33% for the full year.
Cenexi positive EBITDA by Q4 FY25
Cenexi is expected to achieve positive EBITDA by the fourth quarter of this fiscal year.
Cenexi revenue to exceed EUR 200 million in FY26
Cenexi expects revenue to exceed EUR 200 million in the next fiscal year, driving positive EBITDA.
Cenexi positive EBITDA by Q3 FY26
Management expects Cenexi to deliver positive EBITDA in Q3 FY26, with Q2 being lower due to summer shutdown.
Mid-teen overall revenue growth for FY26
Management reiterated guidance for mid-teen consolidated revenue growth for the full year, driven by U.S. launches and Cenexi recovery.
GLP-1 cartridge capacity expansion to 140M by Mar'26
The new 100 million cartridge line will be ready for commercialization by March 2026, adding to the existing 40 million capacity.
20 million GLP-1 units commercialization in FY27
Management expects to commercialize around 20 million pens/cartridges in FY27, primarily for RoW markets.
Base business EBITDA margin target of 30-32%
Management expects base business EBITDA margins to remain in the 30-32% range, with potential slight decline as lower-margin Enoxaparin supplies resume.
Cenexi revenue run rate of EUR 50-55 million per quarter
CFO guided that Cenexi's normalized quarterly revenue should be around EUR 50-55 million on a full quarter basis.
EUR 60 million investment in Cenexi over 12-18 months
Planned investment of EUR 60 million in CapEx and working capital to enhance capacity and operational efficiencies at Cenexi.
Steady sequential revenue growth for base business
Management expects steady quarter-on-quarter growth in the base business, driven by new launches and volume expansion.
Low double-digit revenue growth for FY25
Management expects full-year revenue growth in low double-digits, driven by new launches, Saudi recovery, and steady U.S. base business.
Cenexi positive EBITDA by Q4 FY25
Cenexi targets positive EBITDA in Q4 FY25, supported by new ampoule line commercial production starting January 2025.
Cenexi EBITDA breakeven next fiscal year
Cenexi aims for EBITDA breakeven in FY26, driven by revenue above EUR 200 million threshold.
Biologics CDMO initial benefits from Q1 FY26
The Dr. Reddy's biologics CDMO collaboration is expected to generate initial financial benefits from Q1 FY26.
Mid-teens consolidated revenue growth for FY26
Management reaffirmed mid-teens revenue growth guidance for FY26, driven by new launches (dalbavancin, colistimethate) and Cenexi improvement.
Cenexi break-even in Q3 FY26
Cenexi is expected to break even in Q3 FY26, supported by EUR 50 million quarterly revenue target and cost initiatives.
Cenexi EBITDA improvement year-on-year
Cenexi EBITDA losses reduced to EUR 5 million in H1 from EUR 11 million last year; management expects continued improvement.
CapEx of INR 2,500M for base business in FY26
Expected CapEx for Gland base business is approximately INR 2,500 million for FY26, focused on capacity expansion.
Cenexi EBITDA breakeven in 12-15 months
Management expects Cenexi to achieve EBITDA breakeven within 12-15 months, with medium-term EBITDA margin target of 10%.
Cenexi incremental revenue of EUR 30-40 million by FY2026
New programs in tech transfer and approval stages are expected to add EUR 30-40 million to Cenexi's annual revenue in the medium term.
Base business mid-teens growth target
Ex-Cenexi business targets mid-teens revenue growth over the next 2-3 years, driven by US complex products and CDMO opportunities.
Cenexi CapEx of EUR 30 million
Cenexi will invest approximately EUR 30 million in new equipment and capacity expansion over the next year.
Cenexi EBITDA breakeven by Q3 FY26
Cenexi is expected to achieve positive EBITDA by Q3 FY26, delayed from earlier Q4 FY25 guidance due to ANSM inspection impact.
Cenexi revenue run rate of EUR 15M per quarter
Management targets Cenexi quarterly revenue above EUR 15 million to support EBITDA breakeven, driven by new high-speed lines.
Biologics CDMO revenue from Dr. Reddy's from FY26
Collaboration with Dr. Reddy's for biologics CDMO is expected to generate incremental revenue starting next financial year (FY26).
15KL additional biologics capacity for Henlius
Planned expansion of biologics drug substance capacity by 15KL to support the Shanghai Henlius collaboration, with revenue likely from FY27-28.
FY27 organic growth of 12-13%
Management expects base business to grow 12-13% in FY27, with potential upside from European CMS approvals and Dalbavancin launch.
Five-year organic CAGR of 15%
Company targets 15% organic CAGR over five years, excluding inorganic contributions, driven by capacity expansions and CDMO contracts.
INR 2,000 crore CapEx over five years
Brownfield expansions include BFS, ophthalmic lines, and CDMO-dedicated capacity; FY27 CapEx expected >INR 400 crore.
Cenexi annualized revenue run-rate of EUR 200M
Cenexi expected to maintain EUR 50 million quarterly run-rate on an annualized basis, with positive EBITDA trajectory.
Base business annual growth of 14-15%
Management expects the base business (ex-Cenexi) to grow at 14-15% annually, driven by new launches and market share gains.
Cenexi to reach high-teen EBITDA margins in 1-2 years
Cenexi targets high-teen EBITDA margins within 1-2 years through operational fixes, tech transfers, and capacity expansion.
Cenexi quarterly revenue to ramp to EUR 50M in ~3 quarters
Cenexi's quarterly revenue is expected to gradually increase from EUR 40M to EUR 50M in about three quarters.
Mid-teens consolidated revenue growth in FY26
Management expects consolidated revenue to grow in the mid-teens percentage range in FY26, driven by new launches, CMO projects, and biologics.
Cenexi positive EBITDA by Q3 FY26
Cenexi is targeting to achieve positive EBITDA by the third quarter of FY26, with double-digit EBITDA margins expected in FY27.
Biologics revenue of INR 100 crore in FY26
The biologics segment, including the Dr. Reddy's collaboration, is expected to contribute approximately INR 100 crore in revenue in FY26.
GLP-1 cartridge capacity expansion to 140M units by CY26
Gland is adding 100 million units of cartridge capacity, reaching 140 million units total by calendar year 2026, to support GLP-1 contracts.
FY27 consolidated revenue growth of 12-13% constant currency
Management expects 12-13% revenue growth in FY27 on constant currency basis, excluding GLP-1 upside.
Cenexi FY27 EBITDA margin mid-single to high-single digit
Cenexi targets mid-single to high-single digit EBITDA margin for FY27, improving from current positive EBITDA.
Cenexi medium-term EBITDA margin mid-teen
Cenexi aims for mid-teen EBITDA margin in the medium term, driven by capacity additions and operational efficiencies.
CapEx of INR 500 crores in FY27
Capital expenditure for FY27 expected to be around INR 500 crores, part of INR 2,000 crores over five years.